Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf et al. · New England Journal of Medicine · 2014 · 3K citations · Full text

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Charles J. Ryan, Matthew R. Smith, Johann S. de Bono et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

Janusz Mezynski, Carmel Pezaro, Diletta Bianchini et al. · Annals of Oncology · 2012 · 246 citations

Metronomic Therapy, Pharmacology, Clinical Evidence +7

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer

Robert J. van Soest, Martin E. van Royen, Ellen S. de Morrée et al. · European Journal of Cancer · 2013 · 203 citations

Urology, Oncology, Medicine +7

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies

Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès et al. · European Urology · 2014 · 164 citations

Medicine, Hormonal Receptor, Patients Progressing +6